PATENT CLAIM ANALYSIS

Application Number: 16207745
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "252060"]

Abstract:
Compounds of formula (I) wherein: R 1  is heteroaryl optionally substituted by methyl, ethyl, halo or ═O; and R 2  is H, methyl or ethyl.and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel disease, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Claim (Index 13):
A pharmaceutical composition comprising:\n a) a therapeutically effective amount of a compound as defined in  claim 6  or a pharmaceutically acceptable salt thereof; and b) at least one pharmaceutically acceptable excipient(s).

Metadata:
- Claim Count in Document: 24.0
- Percentile: 98.0
- Lexical Diversity: 1.67742
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15574947', '15537805', '15900043', '15698435', '11092503']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7608677426685913
- 35 USC 102 Novelty (BERT): 0.5721155938837037
- Combined Prediction Score: 0.7419925277901026
- Mean Citation Score: 364.340882
- Max Citation Score: 459.32516
- Similarity Product: 379.0874509921789

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test